Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Arbutus Biopharma Corpora...

    NASDAQ: ABUS · Real-Time Price · USD
    3.52
    0.07 (2.03%)
    At close: Jun 18, 2025, 11:19 AM

    Arbutus Biopharma Statistics

    Share Statistics

    Arbutus Biopharma has 191.53M shares outstanding. The number of shares has increased by 1.46% in one year.

    Shares Outstanding

    n/a
    		 191.53M

    Shares Change (YoY)

    n/a
    		 1.46%

    Shares Change (QoQ)

    n/a
    		 1.05%

    Owned by Institutions (%)

    n/a
    		 55.07%

    Shares Floating

    n/a
    		 148.66M

    Failed to Deliver (FTD) Shares

    n/a
    		 4,494

    FTD / Avg. Volume

    n/a
    		 0.48%

    Short Selling Information

    The latest short interest is 12.75M, so 6.66% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 12.75M

    Short % of Shares Out

    n/a
    		 6.66%

    Short % of Float

    n/a
    		 9.46%

    Short Ratio (days to cover)

    n/a
    		 15.97

    Valuation Ratios

    The PE ratio is -8.68 and the forward PE ratio is -17.92. Arbutus Biopharma's PEG ratio is 0.64.

    PE Ratio

    n/a
    		 -8.68

    Forward PE

    n/a
    		 -17.92

    PS Ratio

    n/a
    		 98.35

    Forward PS

    n/a
    		 3.8

    PB Ratio

    n/a
    		 6.23

    P/FCF Ratio

    n/a
    		 -9.33

    PEG Ratio

    n/a
    		 0.64
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Arbutus Biopharma.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.15, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 8.15

    Quick Ratio

    n/a
    		 8.15

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 -0.02

    Debt / FCF

    n/a
    		 -0.02

    Interest Coverage

    n/a
    		 -557.07

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $140,250

    Profits Per Employee

    n/a
    		 $-1,589,090.91

    Employee Count

    n/a
    		 44

    Asset Turnover

    n/a
    		 0.05

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 14.95% in the last 52 weeks. The beta is 1.24, so Arbutus Biopharma's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.24

    52-Week Price Change

    n/a
    		 14.95%

    50-Day Moving Average

    n/a
    		 3.31

    200-Day Moving Average

    n/a
    		 3.53

    Relative Strength Index (RSI)

    n/a
    		 52.28

    Average Volume (20 Days)

    n/a
    		 931,038

    Income Statement

    In the last 12 months, Arbutus Biopharma had revenue of 6.17M and earned -69.92M in profits. Earnings per share was -0.38.

    Revenue

    n/a
    		 6.17M

    Gross Profit

    n/a
    		 4.79M

    Operating Income

    n/a
    		 -76.32M

    Net Income

    n/a
    		 -69.92M

    EBITDA

    n/a
    		 -68.4M

    EBIT

    n/a
    		 -69.78M

    Earnings Per Share (EPS)

    n/a
    		 -0.38
    Full Income Statement

    Balance Sheet

    The company has 36.33M in cash and 1.29M in debt, giving a net cash position of 35.04M.

    Cash & Cash Equivalents

    n/a
    		 36.33M

    Total Debt

    n/a
    		 1.29M

    Net Cash

    n/a
    		 35.04M

    Retained Earnings

    n/a
    		 -1.35B

    Total Assets

    n/a
    		 117.01M

    Working Capital

    n/a
    		 97.38M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -64.85M and capital expenditures -182K, giving a free cash flow of -65.03M.

    Operating Cash Flow

    n/a
    		 -64.85M

    Capital Expenditures

    n/a
    		 -182K

    Free Cash Flow

    n/a
    		 -65.03M

    FCF Per Share

    n/a
    		 -0.35
    Full Cash Flow Statement

    Margins

    Gross margin is 77.64%, with operating and profit margins of -1236.74% and -1133.04%.

    Gross Margin

    n/a
    		 77.64%

    Operating Margin

    n/a
    		 -1236.74%

    Pretax Margin

    n/a
    		 -1133.04%

    Profit Margin

    n/a
    		 -1133.04%

    EBITDA Margin

    n/a
    		 -1108.46%

    EBIT Margin

    n/a
    		 -1236.74%

    FCF Margin

    n/a
    		 -1053.83%

    Dividends & Yields

    ABUS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ABUS is $5, which is 44.5% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $5

    Price Target Difference

    n/a
    		 44.5%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Nov 4, 2010. It was a backward split with a ratio of 1:5.

    Last Split Date

    n/a
    		 Nov 4, 2010

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:5

    Scores

    Altman Z-Score

    n/a
    		 9.25

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist